Related Experiment Video
Updated: Apr 29, 2026
09:39
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018
9.1K
TRPA1 in Chemotherapy-Induced Peripheral Neuropathy: A Promising Target for Immunomodulation and Anti-Inflammatory
Huini Yao1, Mingzhu Li2, Shengbo Jin3
1Department of Integrated Traditional Chinese and Western Medicine Medical Oncology, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute; China Medical University.
Journal of Visualized Experiments : Jove
|April 27, 2026
Summary
Chemotherapy-induced peripheral neuropathy (CIPN) causes pain and sensitivity. Targeting the TRPA1 receptor shows promise for treating CIPN by reducing neuroinflammation.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of cancer treatment, characterized by pain and sensory disturbances.
- Current treatments for CIPN are limited, necessitating the exploration of novel therapeutic targets.
Purpose of the Study:
- To investigate the role of Transient Receptor Potential Ankyrin 1 (TRPA1) in the development of CIPN.
- To evaluate the potential of targeting TRPA1 to treat CIPN by inhibiting neuroinflammation.
- To explore the use of TRPA1 antagonists and natural compounds for CIPN management.
Main Methods:
- Examined the role of TRPA1 in CIPN pathogenesis.
- Verified the therapeutic potential of TRPA1 inhibition for CIPN treatment.
- Explored the application of TRPA1 antagonists and natural herbs in preclinical models.
Main Results:
- TRPA1 activation contributes to CIPN by modulating inflammatory pathways and promoting pain signaling.
- Inhibiting TRPA1 demonstrated a reduction in neuroinflammation and associated symptoms.
- Natural compounds targeting TRPA1 showed potential therapeutic effects.
Conclusions:
- TRPA1 is a key mediator in the pathogenesis of CIPN.
- Targeting TRPA1 represents a promising therapeutic strategy for managing CIPN.
- Further research into TRPA1 antagonists and natural products could lead to effective CIPN treatments.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
816
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
816
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.1K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.1K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
920
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
920
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
1.1K
01:43Thermosensation
29.7K
Peripheral thermosensation is the perception of external temperature. A change in temperature (on the surface of the skin and other tissues) is detected by a family of temperature-sensitive ion channels called Transient Receptor Potential, or TRP, receptors. These receptors are located on free nerve endings. Those detecting cold temperatures are closer to the surface of the skin than the nerve endings detecting warmth. These thermoTRP channels, while temperature selective, have relatively...
29.7K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81